OnabotulinumtoxinA treatment of mild glabellar lines in repose.
BACKGROUND
OnabotulinumtoxinA is an established treatment for glabellar frown lines, but its effects on lines at repose are less well documented.


OBJECTIVE
To assess the effect of onabotulinumtoxinA on elimination of mild lines at repose.


METHODS
Data from two randomized, double-blind, placebo-controlled studies were included. Elimination of mild lines at repose was defined as change from mild to none on the Facial Wrinkle Scale.


RESULTS
Analysis included 183 participants who received 20 U of onabotulinumtoxinA and 64 participants who received placebo, all with mild lines at repose at baseline. Participants were evaluated 7, 30, 60, 90, and 120 days posttreatment. Compared to placebo, onabotulinumtoxinA-treated participants were significantly more likely to have their lines at repose eliminated at each study day; [odds ratios ranged from 42.7 (95% confidence interval (CI)=12.9-141.9) at day 30 to 4.9 (95% CI=2.2-10.8) at day 120 (p<.0001 at each day)]. The highest response rate was observed at day 30 (68%).


CONCLUSIONS
OnabotulinumtoxinA has demonstrated the ability to eliminate mild glabellar lines at repose for a significant number of patients. This effect, albeit more subtle than the effect on dynamic or more severe glabellar lines, may be an important treatment goal for patients who seek a smoother appearance at repose.
Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada.
Alastair
A
Carruthers
Jean
J
Carruthers
Xiaofang
X
Lei
Janice M
JM
Pogoda
Nina
N
Eadie
Mitchell F
MF
Brin
D000328:Adult; D000368:Aged; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage*; D004311:Double-Blind Method; D005260:Female; D005546:Forehead; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D009465:Neuromuscular Agents / Q000008:administration & dosage*; D015595:Skin Aging / Q000187:drug effects*; D055815:Young Adult
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A